Brivaracetam belongs to the class of anti-epileptic drugs (AEDs) which have a unique or different mechanism of action compared to the existing treatment options. It has fast onset of action and promising efficacy., , sun pharmaceuticals, drug Brivaracetam, dcgi, Anti-Epilepsy Drug
Sun Pharmaceutical Industries announced that it will introduce the complete range of Brivaracetam dosage forms at an affordable price for epilepsy treatment in India.Brivaracetam is approved by the Drugs Controller General of India (DCGI), as an adjunctive therapy in treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.
Sun Pharma s brand, Brevipil (Brivaracetam) tablet 25 mg/50 mg/75 mg/100 mg was launched in the market on Day-1 post patent expiry of innovator product (21 February 2021). Brevipil oral solution (10 mg/ml) and injectable (10 mg/ml) will be available in the market over the next few weeks.
Brivaracetam belongs to the class of anti-epileptic drugs (AEDs) which have a unique or different mechanism of action compared to the existing treatment options. It has fast onset of action and promising efficacy.
Sun Pharma to launch complete range of generic anti-epilepsy drug
SECTIONS
Last Updated: Feb 23, 2021, 04:06 PM IST
Share
Synopsis
The drug major introduced Brevipil (Brivaracetam) tablet in strengths of 25 mg/50 mg/75 mg/100 mg on February 21, while Brevipil oral solution (10 mg/ml) and injectable (10 mg/ml) will be available in the market over the next few weeks.
Agencies
Brivaracetam is approved by the Drugs Controller General of India (DCGI), as an adjunctive therapy in treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.
Sun Pharmaceutical Industries on Tuesday said it plans to introduce a complete range of anti-epilepsy drug Brivaracetam in the country at an affordable price. The drug major introduced Brevipil (Brivaracetam) tablet in strengths of 25 mg/50 mg/75 mg/100 mg on February 21, while Brevipil oral solution (10 mg/ml) and injectable (10 mg/ml) will be available in the market over the next few weeks.
Sun Pharmaceutical Industries announced that the company will introduce
the complete range of Brivaracetam dosage forms at an affordable price for epilepsy treatment
in India.
Sun Pharma s brand, Brevipil (Brivaracetam) tablet 25 mg/50 mg/75 mg/100 mg
was launched in the market on Day-1 post patent expiry of innovator product (21 February
2021).
Brevipil oral solution (10 mg/ml) and injectable (10 mg/ml) will be available in the
market over the next few weeks.
Brivaracetam is approved by the Drugs Controller General
of India (DCGI), as an adjunctive therapy in treatment of partial-onset seizures in patients 16
years of age and older with epilepsy.
Powered by Capital Market - Live News